TNFRSF9 and neoplasm: As anti-4-1BB (CD137) treatment preferentially drives CD73− effector T cell responses for tumor inhibition, combination with neutralizing anti-CD73 Abs induced more profound tumor regression and led to a great increase in survival as compared to anti-4-1BB therapy alone.